# Valion Bio, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Valion Bio, Inc.). ## Overview Valion Bio, Inc. is a U.S.-based biomedical company developing recombinant biologic and bioelectronic therapies, with a core focus on its TLR5 program and the Entolimod™ family of candidates. The company also operates Velocity Bioworks, a San Antonio, Texas CDMO platform that supports biomanufacturing and related development services. ## Products & services • Entolimod™ recombinant biologic for ARS and oncology-related uses • Entolasta™ optimized Entolimod variant in development • Vagus nerve stimulation-based product candidates • ClearUP consumer device and accessories • CDMO biomanufacturing services through Velocity Bioworks - **Biologic therapeutics** (0%) — Recombinant biologic candidates centered on the TLR5 platform, including Entolimod and Entolasta. - **Bioelectronic therapies** (0%) — Product candidates derived from vagus nerve stimulation research and development. - **Consumer medical devices** (100%) — ClearUP and related accessories sold through direct and reseller channels. - **Contract development and manufacturing** (0%) — Full-service CDMO activities provided through Velocity Bioworks in San Antonio. - Entolimod™ recombinant biologic for ARS and oncology-related uses - Entolasta™ optimized Entolimod variant in development - Vagus nerve stimulation-based product candidates - ClearUP consumer device and accessories - CDMO biomanufacturing services through Velocity Bioworks ## Customers Valion serves two very different customer bases: consumers and channel partners for ClearUP, and future patients, physicians, and institutional buyers for its therapeutic pipeline. Its CDMO operations are aimed at external biopharma clients that need specialized development and manufacturing support. The company’s therapeutic programs also depend on regulators, clinical investigators, and government or defense-related stakeholders for development and approval pathways. - **Consumer health buyers** (primary) — Individuals purchasing ClearUP directly or through online retail channels for personal use. - **Medical resellers and distributors** (primary) — Channel partners such as Simply Medical, Cardinal Health, and other resellers that stock and distribute ClearUP. - **Biopharma CDMO clients** (secondary) — External customers that may use Velocity Bioworks for specialized biomanufacturing and development services. - **Clinical and institutional end users** (emerging) — Hospitals, physicians, and other institutional buyers that could use future Entolimod or Entolasta therapies. - Consumers buying ClearUP for at-home symptom relief - Resellers and distributors such as McKesson-affiliated channels - Retail platforms that list ClearUP for broad consumer reach - Biopharma clients needing CDMO manufacturing support - Clinical and institutional buyers for future Entolimod-based therapies ## Geography Valion is headquartered in the United States and conducts its consumer and development activities primarily from U.S. operations. Its manufacturing footprint includes San Antonio, Texas through Velocity Bioworks, which is intended to support both internal pipeline programs and external CDMO work. The company’s commercial exposure is therefore concentrated in the U.S., while future therapeutic commercialization could extend into regulated global markets. - Headquartered in the United States - San Antonio, Texas is a key operating and manufacturing site - ClearUP is sold through U.S. online and retail channels - Therapeutic development is centered on U.S. regulatory pathways - Future commercialization could expand beyond the U.S. ## Strategy Valion’s strategy is to shift from consumer device monetization toward biologic and bioelectronic drug development with longer-duration commercial potential. It is also building manufacturing control through Velocity Bioworks so it can support Entolimod supply, accelerate development, and potentially generate third-party CDMO revenue. The company is pursuing regulatory advancement, clinical development, and selective licensing or transaction opportunities to support its pipeline. - **Advance the TLR5/Entolimod pipeline** (medium-term) — Clinical progress is the main path to durable value creation beyond the legacy consumer device business. - **Integrate manufacturing through Velocity Bioworks** (short-term) — Direct control of biomanufacturing can improve execution, supply reliability, and commercialization readiness. - **Build third-party CDMO revenue** (medium-term) — External manufacturing services can diversify revenue while the therapeutic pipeline matures. - **Exit or monetize ClearUP** (short-term) — The consumer device business is being wound down, so monetization or divestiture can free capital for the pipeline. - Advance Entolimod and Entolasta into later-stage clinical studies - Use Velocity Bioworks to control manufacturing and supply chain - Monetize CDMO capabilities with external biomanufacturing clients - Reduce reliance on ClearUP and transition away from consumer sales - Pursue licensing and strategic transactions around the TLR5 platform ## Risks Valion faces development-stage biotech risk, including clinical failure, regulatory delay, and manufacturing scale-up challenges for its therapeutic candidates. The company also has concentrated exposure to the wind-down of ClearUP, dependence on external financing, and execution risk in building a CDMO business that must compete on quality, reliability, and compliance. - **Clinical development failure** [high] — Entolimod, Entolasta, and bioelectronic candidates may not demonstrate safety or efficacy in trials. - **Regulatory delay or rejection** [high] — Therapeutic candidates require FDA review, and timelines can shift materially with data or filing issues. - **Financing risk** [critical] — The company has relied on equity and other financing and may need more capital before product revenue scales. - **Consumer business wind-down** [medium] — Exiting ClearUP can reduce near-term revenue and create transition risk in channel inventory sell-through. - **Manufacturing and CDMO execution** [medium] — Biomanufacturing requires strict quality systems, regulatory compliance, and reliable customer delivery. - Clinical trials may fail or produce insufficient efficacy data - FDA approval and IND pathways can delay commercialization - ClearUP wind-down may reduce revenue and brand value - Additional capital may be needed to fund operations and trials - CDMO execution risk includes quality, compliance, and customer retention ## Accounting Valion’s accounting is shaped by a development-stage biotech model, where R&D spending, stock-based compensation, and going-concern judgments can dominate reported results. Inventory and sales return reserves matter for the ClearUP business, while future clinical and manufacturing activities may introduce additional estimates around contract costs, capitalization, and impairment. As the company shifts toward biologics and CDMO work, revenue recognition and reserve assumptions may become more complex and more important to comparability. - **Inventory reserves** — Affects cost of sales and gross margin - **Sales return reserves** — Affects reported net revenue - **Stock-based compensation** — Affects operating expenses and loss measures - **Going-concern and liquidity estimates** — Affects financial statement presentation and risk disclosure - Inventory reserves affect the carrying value of ClearUP stock - Sales return reserves affect net consumer device revenue - Stock-based compensation is a meaningful non-cash expense - Going-concern assessment reflects funding needs and runway - Future CDMO and licensing revenue may require contract judgment --- *Last updated: 2026-06-16T23:12:44.938885+00:00*